GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lonza Group Ltd (OTCPK:LZAGY) » Definitions » EPS (Diluted)

Lonza Group (Lonza Group) EPS (Diluted) : $1.00 (TTM As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Lonza Group EPS (Diluted)?

Lonza Group's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was $0.39. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.00.

Lonza Group's EPS (Basic) for the six months ended in Dec. 2023 was $0.39. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.00.

Lonza Group's EPS without NRI for the six months ended in Dec. 2023 was $0.73. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $1.41.

During the past 12 months, Lonza Group's average EPS without NRIGrowth Rate was -15.80% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 8.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 3.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 10.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Lonza Group's highest 3-Year average EPS without NRI Growth Rate was 24.10% per year. The lowest was -13.20% per year. And the median was 12.70% per year.


Lonza Group EPS (Diluted) Historical Data

The historical data trend for Lonza Group's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lonza Group EPS (Diluted) Chart

Lonza Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 1.31 4.29 1.75 1.03

Lonza Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 0.68 1.04 0.62 0.39

Competitive Comparison of Lonza Group's EPS (Diluted)

For the Diagnostics & Research subindustry, Lonza Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lonza Group's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where Lonza Group's PE Ratio falls into.



Lonza Group EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Lonza Group's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(756.244-0)/736.838
=1.03

Lonza Group's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(282.146-0)/733.604
=0.38

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lonza Group  (OTCPK:LZAGY) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Lonza Group EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Lonza Group's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Lonza Group (Lonza Group) Business Description

Address
Muenchensteinerstrasse 38, Basel, CHE, CH-4002
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.